NW Bio Gets Recommendation To Continue With Last-stage GBM Brain Cancer Trial

(RTTNews) - Northwest Biotherapeutics (NWBO) or NW Bio announced, in response to shareholder inquiries, that the Data Safety Monitoring Board or DSMB has made an unblinded review of the safety data for the company's ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned.

The DSMB's review of the efficacy data is still pending.

Marnix Bosch, Chief Technical Officer of the company said, "We are pleased with the recommendation of the DSMB to continue the trial as planned. This is an important step in the ongoing progress of our Phase III trial."